- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05501704
ETHAN - ET for Male BC
ETHAN: A Phase II Study Comparing Different Endocrine THerapies for mAle Breast caNcer
This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer.
The drugs used in this study are:
- Tamoxifen
- Anastrozole
- Degarelix
- Abemaciclib
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, multicenter, randomized trial for men with stage I-III hormone receptor-positive (HR+)/HER2-negative breast cancer. The trial will have two phases: A 3-week window phase containing endocrine therapy followed by a 4-month treatment phase where participants are treated with one of four endocrine therapy treatment combinations.
Tamoxifen is the standard of care for the treatment of breast cancer in men. Anastrozole is a standard treatment in women with breast cancer and works more effectively than tamoxifen. This study hopes to learn if anastrozole may also be effective in men. Given that gonadal suppression and CDK 4/6 inhibitors have both improved treatment in women with breast cancer, the study hopes to learn how the addition of Degarelix (gonadal suppression) and Abemaciclib (CDK 4/6 inhibitors) work in comparison to standard of care tamoxifen.
The research study procedures include screening for eligibility and study treatment including laboratory evaluations and quality of life questionnaires.
After completion of treatment, participants will be followed for up to 10 years
It is expected that about 60 men will take part in this research study.
Eli Lilly, a pharmaceutical company, is supporting this research study by providing one of the study drugs. This study is also being supported by Johns Hopkins University on behalf of the Translational Breast Cancer Research Consortium (TBCRC).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jose Pablo Leone, MD
- Phone Number: 617-789-2903
- Email: josep_leone@dfci.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Dana Farber Cancer Institute
-
Contact:
- Jose Pablo Leone, MD
- Phone Number: 617-789-2903
-
Principal Investigator:
- Jose Pablo Leone, MD
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Cancer Trials Referral Office
- Phone Number: 855-776-0015
-
Principal Investigator:
- Kathryn Ruddy, MD
-
-
Texas
-
Houston, Texas, United States, 77030-4009
- Recruiting
- M. D. Anderson Cancer Center at University of Texas
-
Contact:
- Clinical Trials Office - M. D. Anderson Cancer Center at the U
- Phone Number: 713-792-3245
-
Principal Investigator:
- Jasmine Sukumar, M.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men aged 18 years or older, with diagnosis of invasive breast cancer who have not undergone surgical resection of the primary tumor and axillary nodes.
- Stage I, II, or III per American Joint Committee on Cancer (AJCC) staging 8th edition (112).
Breast cancer must be hormone receptor-positive and HER2-negative according to definition below assessed by local pathology.
- Hormone receptor-positive is defined as: positivity for at least one of the hormone receptors (estrogen receptor [ER] or progesterone receptor [PR]) by IHC. ER and PR assays are considered positive if there are > 1% positive tumor nuclei in the samples.
- HER2-negative is defined per the current American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline (113).
- Patients with multifocal or multicentric disease are eligible if the treating investigator has determined the patient should be treated as ER-positive and HER2-negative.
- Bilateral breast cancers are allowed if the treating investigator has determined the patient should be treated as ER-positive and HER2-negative.
- Patients with a history of ipsilateral or contralateral DCIS or LCIS are eligible.
- ECOG performance status ≤ 2.
Required laboratory values demonstrating adequate organ function:
- ANC ≥ 1000/mm3
- Hemoglobin ≥ 8 g/dl
- Platelets ≥ 50,000/mm3
- Serum creatinine ≤ 3.0 x ULN (institutional)
- Total bilirubin ≤ 2.0 x ULN (institutional).
- AST and ALT ≤ 5.0 x ULN (institutional)
- Men with partners of childbearing potential must be willing to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for 6 months after the last dose of study treatment.
- Non-English-speaking patients are eligible but will be exempt from patient-completed questionnaires.
- Willing and able to sign informed consent.
- Willing to undergo breast biopsy after completion of window phase.
- Patient is able to swallow oral medications.
Exclusion Criteria:
- Prior endocrine therapy, chemotherapy, radiation therapy, or investigational therapy for the current breast cancer diagnosis.
- Prior endocrine therapy, systemic therapy, radiation therapy, or investigational therapy for any other malignancy within the past 12 months.
- Diagnosis of inflammatory breast cancer (T4d).
- Other concurrent serious diseases that may interfere with planned treatment, including severe cardiac disease, congestive heart failure (CHF) of New York Heart Association (NYHA) Class III or higher, severe pulmonary conditions/illness, uncontrolled infections.
- The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
- The patient has active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.
- The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Window Phase Arm A: Tamoxifen
Participants will be randomly assigned to receive Tamoxifen 1x daily for 3 weeks (21days).
|
Taken orally
Other Names:
|
Experimental: Window Phase Arm B: Anastrozole
Participants will be randomly assigned to receive Anastrozole 1x daily for 3 weeks (21days).
|
Taken orally
Other Names:
|
Experimental: Window Phase Arm C: Anastrozole + Degarelix
Participants will be randomly assigned to receive Anastrozole 1x daily for 3 weeks (21days) and Degarelix on day 1 only.
|
Taken orally
Other Names:
Subcutaneous (under the skin) injection
|
Experimental: Neoadjuvant Phase Arm D: Tamoxifen
Participants will be randomly assigned to receive Tamoxifen 1x daily for 4 cycles (4 months); each study cycle is 28 days.
|
Taken orally
Other Names:
|
Experimental: Neoadjuvant Phase Arm E: Tamoxifen + Abemaciclib
Participants will be randomly assigned to receive Tamoxifen 1x daily and Abemaciclib 2x daily for 4 cycles (4 months); each study cycle is 28 days.
|
Taken orally
Other Names:
Taken orally
Other Names:
|
Experimental: Neoadjuvant Phase Arm F: Anastrozole and Degarelix
Participants will be randomly assigned to receive Anastrozole 1x daily and Degarelix on day 1 of each cycle for 4 cycles (4 months); each study cycle is 28 days.
|
Taken orally
Other Names:
Subcutaneous (under the skin) injection
|
Experimental: Neoadjuvant Phase Arm G: Anastrozole + Degarelix + Abemaciclib
Participants will be randomly assigned to receive Anastrozole 1x daily, Degarelix on day 1 of each cycle and Abemaciclib 2x daily for 4 cycles (4 months); each study cycle is 28 days.
|
Taken orally
Other Names:
Subcutaneous (under the skin) injection
Taken orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Ki-67
Time Frame: At the end of the 3-week window period.
|
Ki-67 will be evaluated by ImmunoHistoChemistry (IHC) following consensus recommendations using imaging analysis methods.
|
At the end of the 3-week window period.
|
RCB index
Time Frame: At time of surgery.
|
RCB will be determined using data from each participating institution pathology department, and will be reviewed by the study team pathologist.
|
At time of surgery.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in estradiol levels
Time Frame: Baseline and at the end of the three-week window period
|
To evaluate the physiologic endocrine changes that occur as a result of treatment with tamoxifen, anastrozole and anastrozole and degarelix as measured by estradiol levels at baseline and at the end of the three-week window period
|
Baseline and at the end of the three-week window period
|
Changes in testosterone levels
Time Frame: Baseline and at the end of the three-week window period
|
To evaluate the physiologic endocrine changes that occur as a result of treatment with tamoxifen, anastrozole and anastrozole and degarelix as measured by testosterone levels at baseline and at the end of the three-week window period
|
Baseline and at the end of the three-week window period
|
Preoperative Endocrine Prognostic Index (PEPI) score
Time Frame: At time of surgery
|
To evaluate the comparative efficacy of the experimental treatments as measured by PEPI score at surgery.
|
At time of surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Grade 3 or Higher Treatment-Related Toxicity Rate
Time Frame: Up to 6 months
|
All grade 3 or higher adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv5 as reported on case report forms were counted.
Rate is the proportion of treated participants experiencing at least one treatment-related grade 3 or higher AE of any type during the time of observation.
|
Up to 6 months
|
Trial enrollment
Time Frame: 3 years
|
We will evaluate how many patients we are able to enroll to this trial in a period of 3 years
|
3 years
|
Trial completion
Time Frame: 3 years
|
We will evaluate how many of the enrolled participants successfully complete the study protocol
|
3 years
|
EORTC QLC-C30 questionnaire
Time Frame: Up to 6 months
|
Patient-reported outcomes (PROs) measures will be conducted using the EORTC QLC-C30 questionnaire.
|
Up to 6 months
|
Adapted EORTC BR23 questionnaire
Time Frame: Up to 6 months
|
Patient-reported outcomes (PROs) measures will be conducted using the EORTC BR23, adapted by replacing female-specific items with male-specific sexual activity/function items from PR25 (Appendix D of protocol) questionnaire.
|
Up to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jose Pablo Leone, MD, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Breast Neoplasms, Male
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Bone Density Conservation Agents
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Tamoxifen
- Anastrozole
Other Study ID Numbers
- 22-225
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Male Breast Cancer
-
Centro Hospitalar Lisboa OcidentalInstituto Nacional de Medicina Legal e Ciências Forenses, Delegação do SulUnknownMale Breast Cancer | Female Breast Cancer
-
University of WashingtonNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Organon and CoInstitute for Applied Economics and Health Research ApsCompleted
-
German Breast GroupPfizerCompletedMale Breast CancerGermany
-
Salah Azaïz Cancer InstituteUnknownMale Breast CancerTunisia
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Tamoxifen
-
Institut Cancerologie de l'OuestActive, not recruiting
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedEstrogen Receptor-positive Breast Cancer | Ductal Breast Carcinoma in SituUnited States
-
Seoul National University HospitalActive, not recruitingHormone Receptor-positive Breast Cancer | Premenopausal Breast CancerKorea, Republic of
-
European Institute of OncologyIstituto Oncologico Veneto IRCCS; Ente Ospedaliero Ospedali Galliera; Istituto...Not yet recruitingDuctal Carcinoma in Situ | RAD51C Gene Mutation | RAD51D Gene Mutation | PALB2 Gene Mutation | Lobular Carcinoma in Situ | ATM Gene Mutation | CDH1 Gene Mutation | CHEK2 Gene Mutation | BRCA MutationItaly
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedBreast Cancer | Stage IV Breast CancerUnited States, Canada, Peru
-
National Cancer Center, KoreaUnknown
-
Northwestern UniversityNational Cancer Institute (NCI); BHR Pharma, LLCRecruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In SituUnited States
-
The Methodist Hospital Research InstituteMillennium Pharmaceuticals, Inc.CompletedEstrogen Receptor Positive Breast CancerUnited States
-
Kafrelsheikh UniversityNot yet recruiting
-
TYK Medicines, IncRecruiting